Encapsulation and release of plasminogen activator from biodegradable magnetic microcarriers.

There are a number of therapies available to recanalize occluded arteries. However, even though proven beneficial, these approaches are not without significant shortcomings. Previous research showed that by encapsulating therapeutic thrombolytic enzymes in liposomic formulations, the reperfusion times in vivo were significantly lower than for administration of free thrombolytic. Like liposomes, biodegradable, diblock polymers of poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) have been shown to have therapeutic benefit as delivery vehicles for a variety of drug delivery concepts. We report on new formulations based on tissue plasminogen activator (tPA) encapsulated in magnetic, PLA-PEG microcarriers. We studied the tPA encapsulation efficiency, loading, and release after varying the molecular weight of polymer, carrier size, tPA solution composition, and use of ultrasound to enhance release. We loaded 3.3-9.4wt% tPA and 12-17wt% magnetite into the carriers, depending on the exact formulation. The release of tPA was complete 20min after reconstitution. Ultrasound insonation failed to enhance tPA release rates in smaller carriers but significantly enhanced release in larger carriers. With these formulations, we should be able to achieve lytic concentrations if we can magnetically concentrate 5mg of carrier within about 11ml of blood volume near the clot.

[1]  J. Loscalzo,et al.  New Therapeutic Agents in Thrombosis and Thrombolysis , 2009 .

[2]  Robert Langer,et al.  Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Erwin K. Kastrup,et al.  Drug facts and comparisons , 1977 .

[4]  D. Christensen,et al.  The role of cavitation in acoustically activated drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[5]  J. Leach,et al.  Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis , 2004, Thrombosis and Haemostasis.

[6]  S. Phillips,et al.  IV tissue plasminogen activator use in acute stroke: Experience from a statewide registry , 2006, Neurology.

[7]  J. A. Ritter,et al.  Analysis of magnetic drug carrier particle capture by a magnetizable intravascular stent: 1. Parametric study with single wire correlation , 2004 .

[8]  Ruxandra Gref,et al.  Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. , 1998, Journal of biomedical materials research.

[9]  Michael D. Kaminski,et al.  Magnetically guided plasminogen activator-loaded designer spheres for acutestroke lysis. , 2007 .

[10]  M. Hennerici,et al.  Ultrasound in the treatment of ischaemic stroke , 2003, The Lancet Neurology.

[11]  E. O’Rear,et al.  Thrombolysis Using Liposomal-Encapsulated Streptokinase: An In Vitro Study , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[12]  K. Ulgen,et al.  The stability of enzymes after sonication , 2000 .

[13]  L. Goldfrank Goldfrank's Toxicologic emergencies , 1986 .

[14]  A. Alexandrov Ultrasound Identification and Lysis of Clots , 2004, Stroke.

[15]  Marc Fatar,et al.  Therapeutic ultrasound in ischemic stroke treatment: experimental evidence. , 2002, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.

[16]  Giles Richardson,et al.  Mathematical modelling of magnetically targeted drug delivery , 2005 .

[17]  D. Crommelin,et al.  Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits: a Comparison with Free t-PA , 1995, Thrombosis and Haemostasis.

[18]  V. Torchilin,et al.  Magnetically driven thrombolytic preparation containing immobilized streptokinase-targeted transport and action. , 1988, Haemostasis.

[19]  R. K. Rana,et al.  Release of Human Serum Albumin from Poly(lactide-co-glycolide) Microspheres , 1990, Pharmaceutical Research.

[20]  G. Blümel,et al.  [Mechanisms of fibrilolysis activation and fibrinolysis inhibition]. , 1978, Die Medizinische Welt.

[21]  V. Yang,et al.  Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[23]  Michael D. Kaminski,et al.  Preparation and characterization of hydrophobic superparamagnetic magnetite gel , 2006 .

[24]  D. Christensen,et al.  Factors affecting acoustically triggered release of drugs from polymeric micelles. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Robert Langer,et al.  Polymeric controlled drug delivery , 1988 .

[26]  J. Leach,et al.  Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase , 2003, Thrombosis and Haemostasis.

[27]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[28]  T. Chung,et al.  Different ratios of lactide and glycolide in PLGA affect the surface property and protein delivery characteristics of the PLGA microspheres with hydrophobic additives , 2006, Journal of microencapsulation.